-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, Tb346gyb2P0NPr1KBgrP9+9eAmRB1ky3B9fm+5baYW7YOud3FA0hP4f7gT9NA66q UeRQJAsAJGdWnBzbvaf43Q== 0000903423-01-500061.txt : 20010514 0000903423-01-500061.hdr.sgml : 20010514 ACCESSION NUMBER: 0000903423-01-500061 CONFORMED SUBMISSION TYPE: DFAN14A PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20010511 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: ICN PHARMACEUTICALS INC CENTRAL INDEX KEY: 0000930184 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 330628076 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: DFAN14A SEC ACT: SEC FILE NUMBER: 001-11397 FILM NUMBER: 1630211 BUSINESS ADDRESS: STREET 1: 3300 HYLAND AVE CITY: COSTA MESA STATE: CA ZIP: 92626 BUSINESS PHONE: 7145450100 MAIL ADDRESS: STREET 1: 3300 HYLAND AVE CITY: COSTA MESA STATE: CA ZIP: 92626 FORMER COMPANY: FORMER CONFORMED NAME: ICN MERGER CORP DATE OF NAME CHANGE: 19940915 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: ICN COMMITTEE TO MAXIMIZE SHAREHOLDER VALUE CENTRAL INDEX KEY: 0001137668 STANDARD INDUSTRIAL CLASSIFICATION: [] FILING VALUES: FORM TYPE: DFAN14A BUSINESS ADDRESS: STREET 1: 730 FIFTH AVENUE CITY: NEW YORK STATE: NY ZIP: 10019 DFAN14A 1 icndfan5-11.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. _____) Filed by the Registrant Filed by a Party other than the Registrant [X] Check the appropriate box: [ ] Preliminary Proxy Statement [ ]Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [ ] Definitive Proxy Statement [X] Definitive Additional Materials [ ] Soliciting Material Under Rule 14a-12 ICN Pharmaceuticals, Inc. - -------------------------------------------------------------------------------- (Name of Registrant as Specified in Its Charter) ICN Committee to Maximize Shareholder Value - -------------------------------------------------------------------------------- (Name of Person(s) Filing Proxy Statement, if Other Than the Registrant) Payment of Filing Fee (Check the appropriate box): [X] No fee required. [ ] Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. (1) Title of each class of securities to which transaction applies: ----------------------------------------------------------------------------- (2) Aggregate number of securities to which transaction applies: ----------------------------------------------------------------------------- (3) Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): ----------------------------------------------------------------------------- (4) Proposed maximum aggregate value of transaction: ----------------------------------------------------------------------------- (5) Total fee paid: ----------------------------------------------------------------------------- [ ] Fee paid previously with preliminary materials: ----------------------------------------------------------------------------- [ ] Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the form or schedule and the date of its filing. (1) Amount previously paid: ----------------------------------------------------------------------------- (2) Form, Schedule or Registration Statement No.: ----------------------------------------------------------------------------- (3) Filing Party: ----------------------------------------------------------------------------- (4) Date Filed: ----------------------------------------------------------------------------- EXPLANATORY NOTE The Committee has amended the Committee Website (www.icnmaxvalue.com), which was filed on a Schedule 14A with the Securities and Exchange Commission ("SEC") on May 8, 2001, to include an additional web page which was made available to shareholders on or about May 11, 2001. The additional contents of the Committee Website have previously been filed with the SEC, or are included with this filing, as follows: Proxy Statement --------------- Letter to Stockholders (May 3, 2001) ------------------------------------ We urge you to read the proxy statement If you wish to cast your vote "FOR" the Committee Nominees, please contact your broker or contact MacKenzie Partners. [MacKenzie Partners, Inc. logo] 156 Fifth Avenue, New York New York 10010 proxy@mackenziepartners.com Call Collect: (212) 929-5500 or Toll-Free: (800) 322-2885 Facsmile: (212) 929-0308 If you wish to vote "FOR" the Committee Nominees you must submit the Committee's proxy card and must NOT submit ICN Pharmaceutical's proxy card for any reason, including to withhold your vote for ICN Pharmaceutical's slate. If you have already returned ICN Pharmaceutical's proxy card, you have the right to revoke it by subsequently signing, dating and mailing the Committee's proxy card. Only your latest dated proxy will count at the 2001 Annual Meeting. Only holders of ICN stock as of the close of business on April 23, 2001 may vote. Your vote is IMPORTANT Cast your vote "FOR" the Committee Nominees! -----END PRIVACY-ENHANCED MESSAGE-----